64
Riferimenti bibliografici
1. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM, Jr., Self SG, Corey L. 2008. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3:e2230.2. Andersen H., Dempsey D., Chervenak R. and Jennings S. R. 2000. Expression of intracellular IFN-gamma in HSV-1-specific CD8+ T cells identifies distinct responding subpopulations during the primary response to infection. J Immunol 165, 2101-2107. 3. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447-458.
4. Alba R, Bosch A, Chillon M. 2005. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12 Suppl 1:S18-27.
5. Anson DS. 2004. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2:9.
6. Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Barucca V, Chiarini F, Pietropaolo V. 2009. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. Virol J 6:40.
7. Arduino PG, Porter SR. 2008. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 37:107-121.
8. Aurelian L. 2004. Herpes simplex virus type 2 vaccines: new ground for optimism?
Clin Diagn Lab Immunol 11:437-445.
9. Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM. 2008. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 26:1195-1203.
10. Bangari DS, Mittal SK. 2006. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 6:215-226.
11. Barquinero J, Eixarch H, Perez-Melgosa M. 2004. Retroviral vectors: new applications for an old tool. Gene Ther 11 Suppl 1:S3-9.
12. Barraza RA, Poeschla EM. 2008. Human gene therapy vectors derived from feline lentiviruses. Vet Immunol Immunopathol 123:23-31.
13. Barrow RY, Berkel C, Brooks LC, Groseclose SL, Johnson DB, Valentine JA. 2008. Traditional sexually transmitted disease prevention and control strategies: tailoring for African American communities. Sex Transm Dis 35:S30-39.
14. Beauman JG. 2005. Genital herpes: a review. Am Fam Physician 72:1527-1534. 15. Bendinelli M, Pistello M, Lombardi S, Poli A, Garzelli C, Matteucci D, Ceccherini-Nelli L, Malvaldi G, Tozzini F. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 8:87-112.
16. Berges BK, Wolfe JH, Fraser NW. 2007. Transduction of brain by herpes simplex virus vectors. Mol Ther 15:20-29.
17. Bouard D, Alazard-Dany D, Cosset FL. 2009. Viral vectors: from virology to transgene expression. Br J Pharmacol 157:153-165.
18. Breckpot K, Aerts JL, Thielemans K. 2007. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 14:847-862.
65 19. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. 2008. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.
J Virol 82:8431-8441.
20. Brown Z. 2004. Preventing herpes simplex virus transmission to the neonate. Herpes 11 Suppl 3:175A-186A.
21. Camerini V, Decimo D, Balvay L, Pistello M, Bendinelli M, Darlix JL, Ohlmann T. 2008. A dormant internal ribosome entry site controls translation of feline immunodeficiency virus. J Virol 82:3574-3583.
22. Campos SK, Barry MA. 2007. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7:189-204.
23. Celum C, Levine R, Weaver M, Wald A. 2004. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 82:447-453.
24. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. 2004. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex
Reprod Health 36:11-19.
25. Chibo D, Druce J, Sasadeusz J, Birch C. 2004. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 61:83-91.
26. Chong EM, Wilhelmus KR, Matoba AY, Jones DB, Coats DK, Paysse EA. 2004. Herpes simplex virus keratitis in children. Am J Ophthalmol 138:474-475.
27. Chong H, Starkey W, Vile RG. 1998. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 72:2663-2670.
28. Clement C, Tiwari V, Scanlan PM, Valyi-Nagy T, Yue BY, Shukla D. 2006. A novel role for phagocytosis-like uptake in herpes simplex virus entry. J Cell Biol 174:1009-1021.
29. Cronin J, Zhang XY, Reiser J. 2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5:387-398.
30. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. 2000. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 1:31-38. 31. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, Billaudel S, Chanzy B, Coste-Burel M, Finkielsztejn L, Fleury H, Hadou T, Henquell C, Lafeuille H, Lafon ME, Le Faou A, Legrand MC, Maille L, Mengelle C, Morand P, Morinet F, Nicand E, Omar S, Picard B, Pozzetto B, Puel J, Raoult D, Scieux C, Segondy M, Seigneurin JM, Teyssou R, Zandotti C. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 42:242-249.
32. Da Ros CT, Schmitt Cda S. 2008. Global epidemiology of sexually transmitted diseases. Asian J Androl 10:110-114.
33. De Palma M, Montini E, Santoni de Sio FR, Benedicenti F, Gentile A, Medico E, Naldini L. 2005. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105:2307-2315.
34. Dinotta F, De Pasquale R, Nasca MR, Tedeschi A, Micali G. 2009. Disseminated herpes simplex infection in a HIV+ patient. G Ital Dermatol Venereol 144:205-209.
35. Dohner K, Radtke K, Schmidt S, Sodeik B. 2006. Eclipse phase of herpes simplex virus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26. J Virol 80:8211-8224.
66 36. Elder JH, Sundstrom M, de Rozieres S, de Parseval A, Grant CK, Lin YC. 2008. Molecular mechanisms of FIV infection. Vet Immunol Immunopathol 123:3-13.
37. Emoto K, Tateno C, Hino H, Amano H, Imaoka Y, Asahina K, Asahara T, Yoshizato K. 2005. Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human hepatocytes. Hum Gene Ther 16:1168-1174.
38. Epstein AL. 2009. HSV-1 derived amplicon vectors: recent technological improvements and remaining difficulties--a review. Mem Inst Oswaldo Cruz 104:399-410. 39. Fatahzadeh M, Schwartz RA. 2007. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the
American Academy of Dermatology 57:737-763.
40. Fink DJ, Mata M. 2008. HSV gene transfer in the treatment of chronic pain. Sheng
Li Xue Bao 60:610-616.
41. Flotte TR. 2005. Adeno-associated virus-based gene therapy for inherited disorders.
Pediatr Res 58:1143-1147.
42. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 20:73-83.
43. Frobert E, Thouvenot D, Lina B, Morfin F. 2007. [Genotyping diagnosis of acyclovir resistant herpes simplex virus]. Pathol Biol (Paris) 55:504-511.
44. Galy B. 2000. IRES elements: fine-tuning of gene expression at the translational level. Trends Biochem Sci 25:426.
45. Gemeniano MC, Sawai ET, Leutenegger CM, Sparger EE. 2003. Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity. J Virol 77:8819-8830.
46. Gierynska M., Kumaraguru U., EoS. K., Lee S., Krieg A., Rouse B. T. 2002. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol 76, 6568-6576.
47. Giordani NV, Neumann DM, Kwiatkowski DL, Bhattacharjee PS, McAnany PK,
Hill JM, Bloom DC. 2008. During herpes simplex virus type 1 infection of rabbits, the ability to express the latency-associated transcript increases latent-phase transcription of lytic genes. J Virol 82:6056-6060.
48. Goncalves MA. 2005. Adeno-associated virus: from defective virus to effective vector. Virol J 2:43.
49. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. 2005. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 12:189-211.
50. Gupta R, Warren T, Wald A. 2007. Genital herpes. Lancet 370:2127-2137.
51. Han JY, Sloan DD, Aubert M, Miller SA, Dang CH, Jerome KR. 2007. Apoptosis and antigen receptor function in T and B cells following exposure to herpes simplex virus.
Virology 359:253-263.
52. Handsfield HH, Waldo AB, Brown ZA, Corey L, Drucker JL, Ebel CW, Leone PA, Stanberry LR, Whitley RJ. 2005. Neonatal herpes should be a reportable disease. Sex
Transm Dis 32:521-525.
53. Hildinger M, Auricchio A. 2004. Advances in AAV-mediated gene transfer for the treatment of inherited disorders. Eur J Hum Genet 12:263-271.
54. Hofemeister H, O'Hare P. 2008. Nuclear pore composition and gating in herpes simplex virus-infected cells. J Virol 82:8392-8399.
67 55. Holub M, Labska K, Roubalova K. 2008. [Recurrent genital herpes]. Klin Microbiol
Infekc Lek 14:52-59.
56. Jacome A, Navarro S, Rio P, Yanez RM, Gonzalez-Murillo A, Lozano ML, Lamana ML, Sevilla J, Olive T, Diaz-Heredia C, Badell I, Estella J, Madero L, Guenechea G, Casado J, Segovia JC, Bueren JA. 2009. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther 17:1083-1092.
57. Jazayeri M, Solehimanjahi H, Fotohui F, Pakravan N. 2009. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice. Comp Immunol Microbiol Infect Dis 32:453-461
58. Johnson AJ, Chu CF, Milligan GN. 2008. Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.
J Virol 82:9678-9688.
59. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546.
60. Johnson LG, Olsen JC, Naldini L, Boucher RC. 2000. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther 7:568-574.
61. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, Campbell KP, Davidson BL, Sauter SL. 1999. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 73:4991-5000.
62. Jones CA, Cunningham AL. 2004. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11:12-17.
63. Jozkowicz A, Dulak J. 2005. Helper-dependent adenoviral vectors in experimental gene therapy. Acta Biochim Pol 52:589-599.
64. Kappes JC, Wu X. 2001. Safety considerations in vector development. Somat Cell
Mol Genet 26:147-158.
65. Kawana T. 2009. [Genital herpes]. Nippon Rinsho 67:143-152.
66. Kay MA, Glorioso JC, Naldini L. 2001. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33-40.
67. Khare PD, Loewen N, Teo W, Barraza RA, Saenz DT, Johnson DH, Poeschla EM. 2008. Durable, safe, multi-gene lentiviral vector expression in feline trabecular meshwork.
Mol Ther 16:97-106.
68. Kim T. W., Hung C. F., Kim J. W., Juang J., Chen P. J., He L., Boyd D. A., Wu T. C. 2004. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 15:167-177.
69. Kimberlin D. 2004. Herpes simplex virus, meningitis, encephalitis in neonates.
Herpes 11 Suppl 2:65A-76A.
70. Kimberlin DW. 2004. Neonatal herpes simplex infection. Clin Microbiol Rev 17:1-13.
71. Kyrkanides S, Miller JH, Brouxhon SM, Olschowka JA, Federoff HJ. 2005. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Brain
68 72. Lachmann R. 2004. Herpes simplex virus-based vectors. Int J Exp Pathol 85:177-190.
73. Levin MJ, Bacon TH, Leary JJ. 2004. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 39 Suppl 5:S248-257. 74. Li W., Minova-Foster T. J., Norton D. D., Muggeridge M. I. 2006. Identification of functional domains in herpes simplex virus 2 glycoprotein B. J Virol 80: 3792-3800. 75. Loewen N, Leske DA, Cameron JD, Chen Y, Whitwam T, Simari RD, Teo WL, Fautsch MP, Poeschla EM, Holmes JM. 2004. Long-term retinal transgene expression with FIV versus adenoviral vectors. Mol Vis 10:272-280.
76. Lolis MS, Gonzalez L, Cohen PJ, Schwartz RA. 2008. Drug-resistant herpes simplex virus in HIV infected patients. Acta Dermatovenerol Croat 16:204-208.
77. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805-812, A.
78. Lundberg C, Bjorklund T, Carlsson T, Jakobsson J, Hantraye P, Deglon N, Kirik D. 2008. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8:461-473.
79. Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. 2007. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol 49:46-55.
80. Matteucci D, Baldinotti F, Mazzetti P, Pistello M, Bandecchi P, Ghilarducci R, Poli A, Tozzini F, Bendinelli M. 1993. Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J Clin Microbiol 31:494-501. 81. Mayaud P, Mabey D. 2004. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect 80:174-182.
82. Martin JM, Villalon G, Jorda E. 2009. [Update on the treatment of genital herpes].
Actas Dermosifiliogr 100:22-32.
83. Mingozzi F, High KA. 2007. Immune responses to AAV in clinical trials. Curr Gene
Ther 7:316-324.
84. Mitsui M, Tsukahara Y. 2009. [STD and mother to child transmission]. Nippon
Rinsho 67:177-184.
85. Muir LA, Chamberlain JS. 2009. Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med 11:e18
86. Mullick S, Watson-Jones D, Beksinska M, Mabey D. 2005. Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect 81:294-302.
87. Muzyczka N, Warrington KH, Jr. 2005. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 16:408-416. 88. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV. 2005. Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum 48:2289-2293.
89. Naldini L. 1998. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 9:457-463.
90. Newman LM, Berman SM. 2008. Epidemiology of STD disparities in African American communities. Sex Transm Dis 35:S4-12.
91. Nicola AV, Straus SE. 2004. Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J Virol 78:7508-7517.
69 92. Ochsendorf FR. 2008. Sexually transmitted infections: impact on male fertility.
Andrologia 40:72-75.
93. Orr M. T., Orgun N. N., Wilson C. B., Way, S. S. 2007. Cutting Edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178, 4731-5.
94. Pack C. D., Gierynska M. and Rouse B. T. 2008. An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus. Hum Vaccin 4: 360-364.
95. Pages JC, Bru T. 2004. Toolbox for retrovectorologists. J Gene Med 6 Suppl 1:S67-82.
96. Paul TA, Casey JW, Avery RJ, Sutton CA. 2007. Expression of feline immunodeficiency virus Vif is associated with reduced viral mutation rates without restoration of replication of vif mutant viruses. Virology 361:112-122.
97. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. 2008. Herpes simplex virus type 2: epidemiology and management options in developing countries. Postgrad Med J 84:299-306.
98. Pistello M. 2008. Should accessory proteins be structural components of lentiviral vaccines? Lessons learned from the accessory ORF-A protein of FIV. Vet Immunol
Immunopathol 123:144-149.
99. Pistello M, Vannucci L, Ravani A, Bonci F, Chiuppesi F, Del Santo B, Freer G, Bendinelli M. 2007. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet Vaccines
Ther 5:8.
100. Remillard-Labrosse G, Guay G, Lippe R. 2006. Reconstitution of herpes simplex virus type 1 nuclear capsid egress in vitro. J Virol 80:9741-9753.
101. Riera-Mestre A, Gubieras L, Martinez-Yelamos S, Cabellos C, Fernandez-Viladrich P. 2009. Adult herpes simplex encephalitis: Fifteen years' experience. Enferm Infecc
Microbiol Clin 27:143-147.
102. Risbud A. 2005. Human immunodeficiency virus (HIV) & sexually transmitted diseases (STDs). Indian J Med Res 121:369-376.
103. Rupp R, Rosenthal SL, Stanberry LR. 2005. Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis 16:31-37.
104. Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I. 2008. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med 8:690-697.
105. Sauter SL, Gasmi M. 2001. FIV vector systems. Somat Cell Mol Genet 26:99-129. 106. Schaffer DV, Koerber JT, Lim KI. 2008. Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 10:169-194.
107. Sen P, Barton SE. 2007. Genital herpes and its management. Bmj 334:1048-1052. 108. Simonsen M, Nahas SC, Silva Filho EV, Araujo SE, Kiss DR, Nahas CS. 2008. Atypical perianal herpes simplex infection in HIV-positive patients. Clinics (Sao Paulo) 63:143-146.
109. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell
Microbiol 6:401-410.
110. Stanberry LR. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl 3:161A-169A.
111. Stein CS, Kang Y, Sauter SL, Townsend K, Staber P, Derksen TA, Martins I, Qian J, Davidson BL, McCray PB, Jr. 2001. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 3:850-856.
70 112. Taylor JM, Lin E, Susmarski N, Yoon M, Zago A, Ware CF, Pfeffer K, Miyoshi J, Takai Y, Spear PG. 2007. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2:19-28.
113. Thomas CE, Ehrhardt A, Kay MA. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346-358.
114. Thompson RL, Preston CM, Sawtell NM. 2009. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog 5:e1000352.
115. Tilson EC, Sanchez V, Ford CL, Smurzynski M, Leone PA, Fox KK, Irwin K, Miller WC. 2004. Barriers to asymptomatic screening and other STD services for adolescents and young adults: focus group discussions. BMC Public Health 4:21.
116. Toka F. N., Gierynska M., Suvas S., Schoenberger S. P., Rouse B. T. 2005. Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 331:151-158.
117. Verhoeyen E, Cosset FL. 2004. Surface-engineering of lentiviral vectors. J Gene
Med 6 Suppl 1:S83-94.
118. Wang G, Slepushkin V, Zabner J, Keshavjee S, Johnston JC, Sauter SL, Jolly DJ, Dubensky TW, Jr., Davidson BL, McCray PB, Jr. 1999. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 104:R55-62.
119. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Jama 296:964-973.
120. Zaiss AK, Muruve DA. 2008. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 15:808-816.
121. Zhang X, Zhao P, Kennedy C, Chen K, Wiegand J, Washington G, Marrero L, Cui Y. 2008. Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther 15:73-84.
122. Ziyaeyan M, Alborzi A, Japoni A, Kadivar M, Davarpanah MA, Pourabbas B, Abassian A. 2007. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Int J Dermatol 46:1263-1266.
123. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873-9880.
